Literature DB >> 12701053

Disodium ascorbyl phytostanyl phosphate reduces plasma cholesterol concentrations and atherosclerotic lesion formation in apolipoprotein E-deficient mice.

Tatjana Lukic1, Kishor M Wasan, Daniela Zamfir, Mohammed H Moghadasian, P Haydn Pritchard.   

Abstract

Disodium ascorbyl phytostanyl phosphate (FM-VP4) consists of ascorbic acid covalently bound to phytostanols by a phosphodiester linkage and is derived as the disodium salt. The purpose of this study was to evaluate the lipid-lowering and antiatherosclerotic properties of FM-VP4 following administration to apolipoprotein E (ApoE)-deficient mice. Four-week-old male C57BL/6J mice with a homozygous deletion of the ApoE gene (apolipoprotein E knock-out) were administered 0 (control), 0.1%, 0.5%, 1.0%, and 2.0% (wt/vol) FM-VP4 in their drinking water or 2.0% FM-VP4 (wt/wt) in their diet for 12 consecutive weeks. All animals received a standard mouse chow diet consisting of 9.0% (wt/wt) fat and 0.2% (wt/wt) cholesterol. Plasma cholesterol and triglyceride levels were determined at baseline and at 4-week intervals (4, 8, and 12 weeks) throughout the term of the study. At the end of the study, mice were killed using CO(2) gas, and blood was taken from the heart. The heart and aorta were removed and sections of the aortic roots were stained with oil red O (ORO) and Movat's stain. The lesions found in this area were measured using a computer-assisted image analysis. Consumption of FM-VP4 by either food or drinking water routes was associated with an approximately 75% reduction in total plasma cholesterol levels and a 75% decrease in aortic atherosclerotic lesion area in ApoE-deficient mice over 12 weeks compared to controls. A trend in decreasing plasma triglyceride levels was also observed. Taken together these data suggest that FM-VP4 has both lipid-lowering and antiatherosclerotic properties following 12-week administration to ApoE-deficient mice. Copyright 2003 Elsevier, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12701053     DOI: 10.1053/meta.2003.50084

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  8 in total

Review 1.  LDL-C-lowering therapy: current and future therapeutic targets.

Authors:  Maartje E Visser; Lily Jakulj; John J P Kastelein; Erik S G Stroes
Journal:  Curr Cardiol Rep       Date:  2008-11       Impact factor: 2.931

Review 2.  Triglyceride-Lowering Response to Plant Sterol and Stanol Consumption.

Authors:  Todd C Rideout; Christopher P F Marinangeli; Scott V Harding
Journal:  J AOAC Int       Date:  2015-05-04       Impact factor: 1.913

3.  Effects of a water-soluble phytostanol ester on plasma cholesterol levels and red blood cell fragility in hamsters.

Authors:  Naoyuki Ebine; Xiaoming Jia; Isabelle Demonty; Yanwen Wang; Peter J H Jones
Journal:  Lipids       Date:  2005-02       Impact factor: 1.880

Review 4.  Inhibition of cholesterol absorption: targeting the intestine.

Authors:  Stephen D Lee; Pavel Gershkovich; Jerald W Darlington; Kishor M Wasan
Journal:  Pharm Res       Date:  2012-08-25       Impact factor: 4.200

5.  Dietary supplementation with phytosterol and ascorbic acid reduces body mass accumulation and alters food transit time in a diet-induced obesity mouse model.

Authors:  Sheila J Thornton; Ian Ty Wong; Rachel Neumann; Petri Kozlowski; Kishor M Wasan
Journal:  Lipids Health Dis       Date:  2011-06-28       Impact factor: 3.876

6.  The effect of two novel cholesterol-lowering agents, disodium ascorbyl phytostanol phosphate (DAPP) and nanostructured aluminosilicate (NSAS) on the expression and activity of P-glycoprotein within Caco-2 cells.

Authors:  Kristina Sachs-Barrable; Jerald W Darlington; Kishor M Wasan
Journal:  Lipids Health Dis       Date:  2014-10-01       Impact factor: 3.876

7.  Protonated nanostructured aluminosilicate (NSAS) reduces plasma cholesterol concentrations and atherosclerotic lesions in Apolipoprotein E deficient mice fed a high cholesterol and high fat diet.

Authors:  Olena Sivak; Jerry Darlington; Pavel Gershkovich; Panayiotis P Constantinides; Kishor M Wasan
Journal:  Lipids Health Dis       Date:  2009-07-28       Impact factor: 3.876

8.  Efficacy and safety of disodium ascorbyl phytostanol phosphates in men with moderate dyslipidemia.

Authors:  Maud N Vissers; Mieke D Trip; P Haydn Pritchard; Patrick Tam; Tatjana Lukic; Monique G de Sain-van der Velden; Martina de Barse; John J P Kastelein
Journal:  Eur J Clin Pharmacol       Date:  2008-03-05       Impact factor: 2.953

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.